Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2006; 12(1): 94-98
Published online Jan 7, 2006. doi: 10.3748/wjg.v12.i1.94
Published online Jan 7, 2006. doi: 10.3748/wjg.v12.i1.94
Table 1 Characteristics of the patients and levels of L1 expression n(%)
| Variable | Patients | L1-positive tumors |
| Total | 63 | 5 (7.9) |
| Male | 32(50.8) | 4 (12.5) |
| Female | 31(49.2) | 1 (3.2) |
| WHO classification of neuroendocrine pancreatic tumour | ||
| Well-differentiated neuroendocrine tumour (grade 1a) | 50(79.4) | 1 (2.0) |
| Well-differentiated neuroendocrine carcinoma (grade 1b) | 4(6.3) | 0 |
| Poorly-differentiated neuroendocrine carcinoma (grade 2) | 9(14.3) | 4 (44.4) |
| Hormone production | ||
| Yes | 11(17.5) | 0 |
| No | 52(82.5) | 5 (9.6) |
| Multiple endocrine neoplasia (MEN)-I | ||
| MEN-I | 6(9.5) | 0 |
| No MEN-I | 57(90.5) | 5 (8.8) |
- Citation: Kaifi JT, Zinnkann U, Yekebas EF, Schurr PG, Reichelt U, Wachowiak R, Fiegel HC, Petri S, Schachner M, Izbicki JR. L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. World J Gastroenterol 2006; 12(1): 94-98
- URL: https://www.wjgnet.com/1007-9327/full/v12/i1/94.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i1.94